Endo Health Solutions
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Endo Health Solutions missed estimates on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue shrank slightly and GAAP earnings per share grew significantly.
Margins grew across the board.
Endo Health Solutions booked revenue of $750.5 million. The 23 analysts polled by S&P Capital IQ expected a top line of $788.9 million on the same basis. GAAP reported sales were 1.1% lower than the prior-year quarter's $759.1 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $1.28. The 24 earnings estimates compiled by S&P Capital IQ predicted $1.26 per share. GAAP EPS of $0.45 for Q3 were 32% higher than the prior-year quarter's $0.34 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 60.8%, 60 basis points better than the prior-year quarter. Operating margin was 26.2%, 260 basis points better than the prior-year quarter. Net margin was 7.2%, 180 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $838.4 million. On the bottom line, the average EPS estimate is $1.64.
Next year's average estimate for revenue is $3.10 billion. The average EPS estimate is $5.03.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 427 members out of 445 rating the stock outperform, and 18 members rating it underperform. Among 134 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 131 give Endo Health Solutions a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Endo Health Solutions is outperform, with an average price target of $40.89.
- Add Endo Health Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Why Endo International plc Jumped and Then Faded -- Twice
The drugmaker can't sustain a rally despite solid third quarter preliminary results.
Here's Why Endo International Stock Dropped as Much as 13.8% Today
The generic pharmaceutical leader is suing the Food and Drug Administration -- and it might be right. Then again, it might not matter.
Is Cannabis The Solution to America's Terrifying Opioid Crisis?
The FDA took an unprecedented step Thursday in an attempt to curb America's opioid abuse crisis, but that doesn't mean medical cannabis will be more seriously considered as an alternative to the highly addictive and deadly drugs.